Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

BACKGROUND: Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of apoptotic cell death is a key mechanism of action of lapa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Eustace, Alex J, Conlon, Neil T, McDermott, Martina S J, Browne, Brigid C, O’Leary, Patrick, Holmes, Frankie A, Espina, Virginia, Liotta, Lance A, O’Shaughnessy, Joyce, Gallagher, Clair, O’Driscoll, Lorraine, Rani, Sweta, Madden, Stephen F, O’Brien, Neil A, Ginther, Charles, Slamon, Dennis, Walsh, Naomi, Gallagher, William M, Zagozdzon, Radoslaw, Watson, William R, O’Donovan, Norma, Crown, John
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6180577/
https://ncbi.nlm.nih.gov/pubmed/30305055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4852-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados